Reisian Sedigheh, Bonakdaran Shokoufeh, Moradi Ali, Yaghoubi Mohammad Ali
Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Clinical Research Development Unit, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
Arch Bone Jt Surg. 2025;13(3):170-175. doi: 10.22038/ABJS.2024.80907.3690.
A rare case of severe prolonged persistent Teriparatide-induced hypercalcemia (14.3mg/dL on admission) in an osteoporotic patient after ceasing the Teriparatide is reported. This 67-year-old female was admitted with polyuria, xerostomia, constipation, progressive weakness, and a history of Triparatide use due to a previous osteoporotic fracture. Her serum calcium, PTH, and vitamin D levels had been normal before starting Teriparatide. Ninety six hours after ceasing the Teriparatide along with rehydration and Calcitonin treatment, the patient's serum calcium levels returned to normal. Severe Teriparatide-induced hypercalcemia does not follow any defined pattern and may persist for days and can usually be controlled through ceasing the Teriparatide, rehydration, and close monitoring of the serum calcium level and symptoms.
报告了一例骨质疏松患者停用特立帕肽后出现严重且持续时间延长的特立帕肽诱导的高钙血症(入院时血钙为14.3mg/dL)的罕见病例。这位67岁女性因先前骨质疏松性骨折使用过特立帕肽,此次因多尿、口干、便秘、进行性肌无力入院。在开始使用特立帕肽之前,她的血清钙、甲状旁腺激素(PTH)和维生素D水平均正常。停用特立帕肽并进行补液及降钙素治疗96小时后,患者血清钙水平恢复正常。严重的特立帕肽诱导的高钙血症没有任何明确的规律,可能会持续数天,通常可通过停用特立帕肽、补液以及密切监测血清钙水平和症状来控制。